USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Anji Henglin Technology Development Co., Ltd.

USPTO PatentsView assignee record - 14 granted patents across 0 technology areas, recorded in grant years 2024–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength.

RSS updates for this company

The verdict

According to USPTO PatentsView, Anji ranks #19,447 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 0 technology areas.

#19,447
of 49,997 US assignees by volume
33rd percentile
by Innovation Score (29.9/100)
1.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R19447 · Foreign Corporation #19,447 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-UNK · INNOV-THIN · CLAIMS-SPARSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

  • GRANTS-MICRO 14 grants
  • MID-PACK #19,447/49,997
  • PHOTO-FINISH Amylin Pharmaceuticals
  • CPC-UNK CPC blank
  • INNOV-THIN 29.9/100
  • CLAIMS-SPARSE 1.0 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • SPAN-YRS 2024–2025 · 2y
  • BOOK-RICH 8/10 fields

Nearest grant-volume peer: Amylin Pharmaceuticals, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Anji’s 29.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Anji

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Anji's Innovation Score is 29.9/100 (33rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Anji?

Each dot is one of Anji’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Anji’s own 1.0 claims/patent is at or below the 18.5 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Anji vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 13.913.91414.1 010203040 Granted patents (volume) Avg claims / patent Amylin Pharmaceuticals, LLC - 14, 11.64Amylin Pharmaceut…AnPac Bio-Medical Science Co., Ltd. - 14, 35.07Anpac Bio-medical…Andrew LLC - 14, 22.14AndrewAneuclose LLC - 14, 5.57AneucloseAon Global Operations SE, Singapore Branch - 14, 18.5Aon Global Operat…Appy Risk Technologies Limited - 14, 18.93Appy RiskArbe Robotics Ltd. - 14, 18.5Arbe RoboticsArch Systems Inc. - 14, 20.21Arch SystemsAnji Henglin Technology Development Co., Ltd. - 14, 1Anji Henglin Tech…
Anji vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Anji's grants concentrate

Anji Henglin Technology Development Co., Ltd. is a focused PatentsView assignee: 0 CPC subclasses . By volume, Anji sits between Amylin Pharmaceuticals, LLC and Arch Systems Inc..

Anji's three-year grant acceleration

Anji Henglin Technology Development Co., Ltd. shows 9 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Anji's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Anji holds 14 patents at rank #19,471, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Anji

By rank, the assignees closest to #19,471 in granted patent volume.

Anji's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 33rd percentile higher than 33% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

45678910 20242025 5
USPTO utility patent grants by year · 2024–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2024–2019 baseline. Full figures in the table below.

View data table
Anji Henglin Technology Development Co., Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2024 9 64.3%
2025partial year 5 35.7%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Anji Henglin Technology Development Co., Ltd.'s patent record in context - here's where to go next.

  • Ranked #19,447 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Anji Henglin Technology Development Co., Ltd. against Amylin Pharmaceuticals, LLC, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 29.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.